4.8 Article

Astrocytic α2-Na+/K+ ATPase inhibition suppresses astrocyte reactivity and reduces neurodegeneration in a tauopathy mouse model

期刊

SCIENCE TRANSLATIONAL MEDICINE
卷 14, 期 632, 页码 -

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.abm4107

关键词

-

资金

  1. NIH [P01 AG03991, P30 AG066444, P01 AG026276, R56NS109007, NS090934]
  2. Cure Alzheimer's Fund
  3. JPB Foundation
  4. Hope Center Viral Vectors Core
  5. Hope Center Alafi Neuroimaging Lab
  6. NIH Shared Instrumentation Grant [S10 RR027552]
  7. NIA [P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949]
  8. NINDS [R01 NS080820]
  9. CurePSP Foundation
  10. Mayo Foundation
  11. National Institute of Neurological Disorders and Stroke [U24 NS072026]
  12. National Institute on Aging [P30 AG19610]
  13. Arizona Department of Health Services [211002]
  14. Arizona Biomedical Research Commission [4001, 0011, 05-901, 1001]
  15. Michael J. Fox Foundation for Parkinsons Research
  16. NCI Cancer Center Support Grant [P30 CA91842]
  17. ICTS/CTSA Grant from the National Center for Research Resources (NCRR), a component of the NIH [UL1TR002345]

向作者/读者索取更多资源

Alzheimer's disease is the most common form of dementia characterized by the deposition of amyloid plaques and neurofibrillary tau tangles. Neuroinflammation, mediated by reactive astrocytes, is an emerging pathophysiological mechanism in AD. This study demonstrates that the elevation of astrocytic alpha 2-Na+/K+ adenosine triphosphatase (alpha 2-NKA) is associated with neuroinflammation and tau pathology in AD, highlighting the important role of reactive astrocytes in the disease progression.
Alzheimer's disease (AD) is the most dominant form of dementia characterized by the deposition of extracellular amyloid plaques and intracellular neurofibrillary tau tangles (NFTs). In addition to these pathologies, an emerging pathophysiological mechanism that influences AD is neuroinflammation. Astrocytes are a vital type of glial cell that contribute to neuroinflammation, and reactive astrocytes, or astrogliosis, are a well-known pathological feature of AD. However, the mechanisms by which astrocytes contribute to the neurodegenerative process in AD have not been fully elucidated. Here, we showed that astrocytic alpha 2-Na+/K+ adenosine triphosphatase (alpha 2-NKA) is elevated in postmortem human brain tissue from AD and progressive nuclear palsy, a primary tauopathy. The increased astrocytic alpha 2-NKA was also recapitulated in a mouse model of tauopathy. Pharmacological inhibition of alpha 2-NKA robustly suppressed neuroinflammation and reduced brain atrophy. In addition, alpha 2-NKA knockdown in tauopathy mice halted the accumulation of tau pathology. We also demonstrated that alpha 2-NKA promoted tauopathy, in part, by regulating the proinflammatory protein lipocalin-2 (Lcn2). Overexpression of Lcn2 in tauopathy mice increased tau pathology, and prolonged Lcn2 exposure to primary neurons promoted tau uptake in vitro. These studies collectively highlight the contribution of reactive astrocytes to tau pathogenesis in mice and define alpha 2-NKA as a major regulator of astrocytic-dependent neuroinflammation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

TFEB regulates lysosomal exocytosis of tau and its loss of function exacerbates tau pathology and spreading

Yin Xu, Shuqi Du, Jacob A. Marsh, Kanta Horie, Chihiro Sato, Andrea Ballabio, Celeste M. Karch, David M. Holtzman, Hui Zheng

Summary: The transcription factor EB (TFEB) plays a crucial role in the lysosomal exocytosis of selected tau species, with TFEB loss causing a decrease in tau levels and accelerated spreading within neurons. This suggests that TFEB-mediated tau exocytosis acts as a clearance mechanism to reduce intracellular tau levels under pathological conditions.

MOLECULAR PSYCHIATRY (2021)

Article Geriatrics & Gerontology

Regional age-related atrophy after screening for preclinical alzheimer disease

Lauren N. Koenig, Pamela LaMontagne, Matthew F. Glasser, Randall Bateman, David Holtzman, Igor Yakushev, Jasmeer Chhatwal, Gregory S. Day, Clifford Jack, Catherine Mummery, Richard J. Perrin, Brian A. Gordon, John C. Morris, Joshua S. Shimony, Tammie L. S. Benzinger

Summary: Brain atrophy is common in aging, especially in temporal lobe and subcortical regions. The rate of atrophy varies in different brain regions, being linear in temporal lobe, faster in subcortical regions at later ages, and slower in frontal regions at later ages. This age-derivative pattern is associated with myelin levels.

NEUROBIOLOGY OF AGING (2022)

Article Medicine, Research & Experimental

Astrocytic 4R tau expression drives astrocyte reactivity and dysfunction

Lubov A. Ezerskiy, Kathleen M. Schoch, Chihiro Sato, Mariana Beltcheva, Kanta Horie, Frank Rigo, Ryan Martynowicz, Celeste M. Karch, Randall J. Bateman, Timothy M. Miller

Summary: This study finds that abnormal expression of 4R tau in astrocytes is associated with the progression of neurodegenerative diseases. Increasing the expression of 4R tau in astrocytes leads to increased expression of neurotoxic genes and dysregulation of homeostatic function. In addition, co-culturing healthy neurons with astrocytes expressing 4R tau results in abnormal firing frequency and hypersynchrony of neurons.

JCI INSIGHT (2022)

Review Immunology

APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease

Samira Parhizkar, David M. Holtzman

Summary: Neuroinflammation is a key mechanism in neurodegenerative diseases such as Alzheimer's disease (AD), and APOE4 directly influences disease onset and progression by interacting with AD's pathological features. Microglia and astrocytes, the immune cells in the brain, play important roles in promoting neuronal health, but under disease conditions, they become dysfunctional and contribute to chronic inflammation-induced neurodegeneration.

SEMINARS IN IMMUNOLOGY (2022)

Article Biochemistry & Molecular Biology

Role of HSP70 chaperone in protein aggregate phenomenon of GNE mutant cells: Therapeutic lead for GNE Myopathy

Rashmi Yadav, Shamulailatpam Shreedarshanee Devi, Jyoti Oswalia, Sivaprakash Ramalingam, Ranjana Arya

Summary: Limited treatment options and research in understanding rare diseases like GNE Myopathy has raised concerns about therapeutic development. The study focuses on the mechanism of protein aggregate formation in GNE mutant cells, revealing HSP70 as a promising therapeutic target in reducing protein aggregation through activators like BGP-15.

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2022)

Article Immunology

Chronic TREM2 activation exacerbates A beta-associated tau seeding and spreading

Nimansha Jain, Caroline A. Lewis, Jason D. Ulrich, David M. Holtzman

Summary: Variants in the TREM2 gene are associated with increased risk for late-onset AD, and decreased function of TREM2 can affect microglial response to Aβ plaques. Chronic increase of TREM2 signaling may exacerbate the Aβ-induced tau pathology.

JOURNAL OF EXPERIMENTAL MEDICINE (2022)

Review Immunology

Emerging roles of innate and adaptive immunity in Alzheimer's disease

Xiaoying Chen, David M. Holtzman

Summary: Alzheimer's disease is the most common neurodegenerative disease with innate immune pathway regulators as genetic risk factors. Innate and adaptive immune responses play important roles in disease development and may serve as therapeutic targets.

IMMUNITY (2022)

Article Biochemistry & Molecular Biology

CSF tau microtubule-binding region identifies pathological changes in primary tauopathies

Kanta Horie, Nicolas R. Barthelemy, Salvatore Spina, Lawren VandeVrede, Yingxin He, Ross W. Paterson, Brenton A. Wright, Gregory S. Day, Albert A. Davis, Celeste M. Karch, William W. Seeley, Richard J. Perrin, Rama K. Koppisetti, Faris Shaikh, Argentina Lario Lago, Hilary W. Heuer, Nupur Ghoshal, Audrey Gabelle, Bruce L. Miller, Adam L. Boxer, Randall J. Bateman, Chihiro Sato

Summary: Currently, there are no fluid biomarkers or imaging tracers available for the diagnosis and treatment of other tauopathies. This study identifies specific tau species that increase in the brains of patients with CBD, PSP, FTLD-MAPT, and AD, but decrease in their cerebrospinal fluid. Measurements of these specific tau species in cerebrospinal fluid can differentiate between different diseases and aid in the diagnosis and clinical trial design of primary tauopathies.

NATURE MEDICINE (2022)

Article Psychiatry

Defective proteostasis in induced pluripotent stem cell models of frontotemporal lobar degeneration

Sidhartha Mahali, Rita Martinez, Melvin King, Anthony Verbeck, Oscar Harari, Bruno A. Benitez, Kanta Horie, Chihiro Sato, Sally Temple, Celeste M. Karch

Summary: Disruption of lysosomal biogenesis and autophagic function is observed in FTLD-tau patients carrying a MAPT p.R406W mutation. Correction of the mutant allele reverses the morphological and functional deficits, and treatment with mTOR inhibitors leads to specific degradation of tau protein in MAPT p.R406W neurons.

TRANSLATIONAL PSYCHIATRY (2022)

Article Biochemical Research Methods

Generation of iPSC-derived human forebrain organoids assembling bilateral eye primordia

Elke Gabriel, Walid Albanna, Giovanni Pasquini, Anand Ramani, Natasa Josipovic, Aruljothi Mariappan, Maria Giovanna Riparbelli, Giuliano Callaini, Celeste M. M. Karch, Olivier Goureau, Argyris Papantonis, Volker Busskamp, Toni Schneider, Jay Gopalakrishnan

Summary: Induced pluripotent stem cell-derived brain organoids, known as OVB organoids, can deconstruct the developmental complexities of the human brain and help study interorgan interactions between optic vesicles and the brain. This protocol enables the generation of functional integrated bilateral optic vesicles and can be used to model early eye patterning defects.

NATURE PROTOCOLS (2023)

Review Biochemistry & Molecular Biology

Emerging diagnostics and therapeutics for Alzheimer disease

Wade K. Self, David M. Holtzman

Summary: Alzheimer disease (AD) is the leading cause of dementia worldwide, and until recently, effective strategies to slow or prevent its clinical progression have been elusive. This review examines the latest advancements in biomarker technologies and therapeutic development for improving AD diagnosis and treatment. It discusses the use of neuroimaging and fluid-based biomarkers to stage AD pathology, focusing on the role of amyloid, tau, and neuroinflammation in disease progression. The review also highlights potential disease-modifying treatment targets and their implications for AD clinical care.

NATURE MEDICINE (2023)

暂无数据